Neuland Laboratories Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 5 Aug 2026

Company page: Neuland Laboratories share price, financials & guidance record

Neuland Laboratories Limited reported a strong Q1 FY27 with total income reaching INR650.1 crores, driven by commercial CMS projects and healthy execution. Profitability saw significant expansion, with EBITDA margin at 35.5% and PAT growing nearly tenfold. The company also improved working capital efficiency and announced a strategic partnership with Gland Pharma for sterile APIs, while maintaining a long-term growth aspiration of 20% and EBITDA margin target of 25% plus.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 119.1%, net profit up 950.0% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	311	398	328	293	514 +65%	440 +11%	776 +137%	642 +119%
Expenses	250	312	278	258	359	363	469	419
EBITDA	61	86	51	34	155 +154%	77 −10%	307 +502%	223 +556%
Margin	20%	22%	15%	12%	30%	18%	40%	35%
Other income	4	60	7	8	2	8	12	8
Interest	1	2	2	5	5	7	7	7
Depreciation	16	16	17	20	23	24	25	27
Profit before tax	49	128	39	17	129 +163%	54 −58%	287 +636%	198 +1065%
Tax rate	34%	20%	29%	21%	25%	26%	26%	25%
Net profit	32	101	28	14	96 +200%	40 −60%	213 +661%	147 +950%
EPS	24.91	79.03	21.61	10.69	75.18	31.50	165.64	114.86

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls